Skip to navigation Skip to content



New Global Research Project Seeks to Identify Best Personal Treatment Options for Individuals with MS

January 26, 2017

A large global new partnership called ‘MultipleMS,’ coordinated by the Karolinska Institute in Sweden, has been awarded 15 million euros to find novel and better treatments for MS. Universities and companies across 12 European countries and the U.S. will unite efforts to develop personalized therapies for people living with MS. The collaborating researchers held a kick-off meeting in Paris on January 24.
With funding from Horizon 2020, a European Union Research and Innovation program, the team will combine clinical, genetic, molecular, MRI and lifestyle data from more than 50,000 people with MS and 30,000 healthy individuals to map out disease characteristics and treatment outcomes. They will use this information to identify predictors that can be used to tailor treatment approaches to the needs of individuals with MS.
Read more about the new project

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.